Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/123567
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGao, Q.en
dc.contributor.authorHanh, J.en
dc.contributor.authorVáradi, L.en
dc.contributor.authorCairns, R.en
dc.contributor.authorSjöström, H.en
dc.contributor.authorLiao, V.en
dc.contributor.authorWood, P.en
dc.contributor.authorBalaban, S.en
dc.contributor.authorOng, J.en
dc.contributor.authorLin, H.en
dc.contributor.authorLai, F.en
dc.contributor.authorHoy, A.en
dc.contributor.authorGrewal, T.en
dc.contributor.authorGroundwater, P.en
dc.contributor.authorHibbs, D.en
dc.date.issued2015en
dc.identifier.citationBioorganic and Medicinal Chemistry, 2015; 23(24):7676-7684en
dc.identifier.issn0968-0896en
dc.identifier.issn1464-3391en
dc.identifier.urihttp://hdl.handle.net/2440/123567-
dc.description.abstractThe three peroxisome proliferator-activated receptor (PPAR) isoforms; PPARα, PPARγ and PPARδ, play central roles in lipid metabolism and glucose homeostasis. Dual PPARα/γ agonists, which stimulate both PPARα and PPARγ isoforms to similar extents, are gaining popularity as it is believed that they are able to ameliorate the unwanted side effects of selective PPARα and PPARγ agonists; and may also be used to treat dyslipidemia and type 2 diabetes mellitus simultaneously. In this study, virtual screening of natural product libraries, using both structure-based and ligand-based drug discovery approaches, identified ten potential dual PPARα/γ agonist lead compounds (9-13 and 16-20). In vitro assays confirmed these compounds to show no statistically significant toxicity to cells, with the exception of compound 12 which inhibited cell growth to 74.5%±3.5 and 54.1%±3.7 at 50μM and 100μM, respectively. In support of their potential as dual PPARα/γ agonists, all ten compounds upregulated the expression of cholesterol transporters ABCA1 and ABCG1 in THP-1 macrophages, with indoline derivative 16 producing the greatest elevation (2.3-fold; 3.3-fold, respectively). Furthermore, comparable to the activity of established PPARα and PPARγ agonists, compound 16 stimulated triacylglycerol accumulation during 3T3-L1 adipocyte differentiation as well as fatty acid β-oxidation in HuH7 hepatocytes.en
dc.description.statementofresponsibilityQuanqing Gao, Jacky Hanh, Linda Váradi, Rose Cairns, Helena Sjöström ... Jennifer Ai Ong ... et al.en
dc.language.isoenen
dc.publisherElsevieren
dc.rights© 2015 Elsevier Ltd. All rights reserved.en
dc.subjectType 2 diabetes; dyslipidemia; cholesterol and fatty acid metabolism; Pan PPAR agonists; virtual screeningen
dc.titleIdentification of dual PPARα/γ agonists and their effects on lipid metabolismen
dc.typeJournal articleen
dc.identifier.rmid1000010279en
dc.identifier.doi10.1016/j.bmc.2015.11.013en
dc.identifier.pubid511882-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS10en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidOng, J. [0000-0002-0958-460X]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.